CO7151509A2 - Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 - Google Patents
Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1Info
- Publication number
- CO7151509A2 CO7151509A2 CO14271199A CO14271199A CO7151509A2 CO 7151509 A2 CO7151509 A2 CO 7151509A2 CO 14271199 A CO14271199 A CO 14271199A CO 14271199 A CO14271199 A CO 14271199A CO 7151509 A2 CO7151509 A2 CO 7151509A2
- Authority
- CO
- Colombia
- Prior art keywords
- difluoro
- hexahydro
- cyclopentaoxacinyls
- benzooxacinyls
- bace1 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona difluoro-ciclopentaoxacinilos y difluoroenzooxacinilos de fórmula (I) que tienen actividad inhibidora BACE1, su fabricación, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico y / o profiláctico de, por ejemplo la enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12173690 | 2012-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7151509A2 true CO7151509A2 (es) | 2014-12-29 |
Family
ID=48672630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14271199A CO7151509A2 (es) | 2012-06-26 | 2014-12-10 | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 |
Country Status (22)
Country | Link |
---|---|
US (1) | US9181232B2 (es) |
EP (1) | EP2864324B1 (es) |
JP (1) | JP6251257B2 (es) |
KR (1) | KR20150023450A (es) |
CN (1) | CN104470915B (es) |
AU (1) | AU2013283524B2 (es) |
BR (1) | BR112014029742A2 (es) |
CA (1) | CA2872181A1 (es) |
CL (1) | CL2014003325A1 (es) |
CO (1) | CO7151509A2 (es) |
CR (1) | CR20140528A (es) |
EA (1) | EA025273B1 (es) |
HK (1) | HK1206344A1 (es) |
IL (1) | IL236138A (es) |
MA (1) | MA37763B1 (es) |
MX (1) | MX2014014937A (es) |
NZ (1) | NZ702253A (es) |
PE (1) | PE20142450A1 (es) |
PH (1) | PH12014502623B1 (es) |
SG (1) | SG11201407576YA (es) |
UA (1) | UA113309C2 (es) |
WO (1) | WO2014001228A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
MX2015011618A (es) | 2013-03-08 | 2015-12-17 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
CA2957544C (en) | 2014-08-08 | 2023-01-24 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
SG11201707050VA (en) | 2015-03-20 | 2017-10-30 | Hoffmann La Roche | Bace1 inhibitors |
JP7353708B2 (ja) * | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体 |
GB0912778D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
US8999980B2 (en) * | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
-
2013
- 2013-06-24 CA CA2872181A patent/CA2872181A1/en not_active Abandoned
- 2013-06-24 WO PCT/EP2013/063086 patent/WO2014001228A1/en active Application Filing
- 2013-06-24 NZ NZ702253A patent/NZ702253A/en not_active IP Right Cessation
- 2013-06-24 JP JP2015519008A patent/JP6251257B2/ja not_active Expired - Fee Related
- 2013-06-24 MX MX2014014937A patent/MX2014014937A/es unknown
- 2013-06-24 UA UAA201500578A patent/UA113309C2/uk unknown
- 2013-06-24 PE PE2014002406A patent/PE20142450A1/es not_active Application Discontinuation
- 2013-06-24 US US14/406,289 patent/US9181232B2/en not_active Expired - Fee Related
- 2013-06-24 SG SG11201407576YA patent/SG11201407576YA/en unknown
- 2013-06-24 EP EP13730887.0A patent/EP2864324B1/en not_active Not-in-force
- 2013-06-24 BR BR112014029742A patent/BR112014029742A2/pt not_active IP Right Cessation
- 2013-06-24 EA EA201590066A patent/EA025273B1/ru not_active IP Right Cessation
- 2013-06-24 KR KR20147036016A patent/KR20150023450A/ko not_active Application Discontinuation
- 2013-06-24 AU AU2013283524A patent/AU2013283524B2/en not_active Expired - Fee Related
- 2013-06-24 CN CN201380033783.7A patent/CN104470915B/zh not_active Expired - Fee Related
- 2013-06-24 MA MA37763A patent/MA37763B1/fr unknown
-
2014
- 2014-11-18 CR CR20140528A patent/CR20140528A/es unknown
- 2014-11-24 PH PH12014502623A patent/PH12014502623B1/en unknown
- 2014-12-05 CL CL2014003325A patent/CL2014003325A1/es unknown
- 2014-12-08 IL IL236138A patent/IL236138A/en not_active IP Right Cessation
- 2014-12-10 CO CO14271199A patent/CO7151509A2/es unknown
-
2015
- 2015-07-21 HK HK15106931.2A patent/HK1206344A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2864324B1 (en) | 2018-03-28 |
CA2872181A1 (en) | 2014-01-03 |
IL236138A0 (en) | 2015-02-01 |
EA025273B1 (ru) | 2016-12-30 |
SG11201407576YA (en) | 2015-03-30 |
CN104470915B (zh) | 2019-07-26 |
EA201590066A1 (ru) | 2015-04-30 |
JP6251257B2 (ja) | 2017-12-20 |
KR20150023450A (ko) | 2015-03-05 |
CL2014003325A1 (es) | 2015-04-24 |
UA113309C2 (xx) | 2017-01-10 |
EP2864324A1 (en) | 2015-04-29 |
PH12014502623A1 (en) | 2015-01-21 |
HK1206344A1 (en) | 2016-01-08 |
BR112014029742A2 (pt) | 2017-06-27 |
AU2013283524B2 (en) | 2017-03-30 |
MA37763B1 (fr) | 2017-05-31 |
US9181232B2 (en) | 2015-11-10 |
IL236138A (en) | 2016-10-31 |
CR20140528A (es) | 2015-01-12 |
PH12014502623B1 (en) | 2015-01-21 |
MA37763A1 (fr) | 2016-08-31 |
PE20142450A1 (es) | 2015-01-28 |
JP2015521640A (ja) | 2015-07-30 |
NZ702253A (en) | 2016-06-24 |
MX2014014937A (es) | 2015-03-09 |
US20150133440A1 (en) | 2015-05-14 |
AU2013283524A1 (en) | 2014-11-13 |
WO2014001228A1 (en) | 2014-01-03 |
CN104470915A (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
CR20130432A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
CO7131369A2 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
PH12015502365B1 (en) | Bace1 inhibitors | |
DOP2015000170A (es) | Compuestos químicos | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
MX2016006906A (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas. | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. |